Lawrence B. Gardner, MD

  • Specialties: Hematology, Leukemia & Lymphoma, Oncology
  • Language: English
  • Phone: 212-731-5650

About Me

Conditions and Treatments

bleeding tendency, deep vein thrombosis (DVT), platelet disorders, anemia, sickle cell anemia, polycythemia vera, myeloproliferative disorder, essential thrombocythemia
Learn more about conditions we treat at NYU Langone:
Sickle Cell Disease

Credentials

Positions

  • Associate Professor, Department of Medicine
  • Associate Professor, Department of Biochemistry and Molecular Pharmacology

Board Certifications

    2001
  • American Board of Internal Medicine (Hematology)

Education and Training

  • 2000
  • Fellowship, Johns Hopkins University, Oncology
  • Fellowship, Johns Hopkins Hospital, Hematology
  • 1994
  • Residency, Johns Hopkins Hospital, Internal Medicine
  • 1993
  • MD from Yale University

Departments

Locations and Appointments

64 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Healthy NY
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Exchange
  • Fidelis Family Health
  • Fidelis Medicaid
  • Fidelis Medicare
  • GHI CBP
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP EPO/PPO
  • HIP Family Health
  • HIP HMO
  • HIP Medicaid
  • HIP Medicare
  • HIP POS
  • HealthPlus Child Health (Amerigroup)
  • HealthPlus Family Health (Amerigroup)
  • HealthPlus Medicaid (Amerigroup)
  • HealthRepublic
  • HealthSmart (WTC)
  • Humana Medicare
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Exchange
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • Tricare
  • United Exchange- Compass
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Visiting Nurse Service (VNS) Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.

NYU Hematology Associates
240 East 38th Street
New York, NY 10016

Contact

Phone: 212-731-5650

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Mechanism and Significance of Hypoxic Regulation of Cell Cycle

We study the effect of low oxygen (hypoxia) on cell cycle regulation, apoptosis, cellular metabolism, and development. Many tumors are severely hypoxic, and hypoxic tumors have a poorer prognosis than non-hypoxic tumors. While most normal cells growth arrest when hypoxic, we have demonstrated that some neoplastic cells, as well as cells we have manipulated with oncogenes, can proliferate even when hypoxic. Using biochemistry, molecular biology, and cell biology techniques we have delineated two specific cell cycle checkpoints that are activated in hypoxic cells: an Rb mediated G1 arrest, and an S phase arrest that is due to the suppression of the initiation step of DNA replication. We are determining how the DNA initiation complex is altered in hypoxic cells, and the role of the ATR kinase (which we have observed is activated in hypoxic cells) in this alteration. We have also determined that the helix-loop-helix inhibitor, Id-1, is transcriptionally down-regulated in hypoxic cells. This down-regulation is dependent on activation of the activation of the unfolded-protein response, and we and are exploring the mechanism and significance of this observation.

Publications

  • Phosphorylation of eIF2alpha triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma

    Wengrod, Jordan; Wang, Ding; Weiss, Sarah; Zhong, Hua; Osman, Iman; Gardner, Lawrence B 2015; ?-?, Science signaling — id: 1495922, year: 2015, page: ?, stat: Journal Article
  • PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition

    Gold, Heidi L; Wengrod, Jordan; de Miera, Eleazar Vega-Saenz; Wang, Ding; Fleming, Nathaniel; Sikkema, Lisa; Kirchhoff, Tomas; Hochman, Tsivia; Goldberg, Judith D; Osman, Iman; Gardner, Lawrence B 2014 Mar; 433-439, Molecular cancer research — id: 883502, year: 2014, page: 433, stat: Journal Article
  • Identification and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense p53 Mutations

    Martin, Leenus; Grigoryan, Arsen; Wang, Ding; Wang, Jinhua; Breda, Laura; Rivella, Stefano; Cardozo, Timothy; Gardner, Lawrence B 2014 Jun; 3104-3113, Cancer research — id: 1032302, year: 2014, page: 3104, stat: Journal Article
Read All Publications (29)